BOSTON SCIENTIFIC CORP 8-K

What Happened

• Boston Scientific Corporation announced results from two clinical trials — HI-PEITHO and CHAMPION-AF — via press releases issued on March 28, 2026. The company filed a Current Report on Form 8-K on March 30, 2026 to disclose those press releases.
• Copies of the two press releases are included as Exhibits 99.1 and 99.2 to the 8-K. The filing notes that information on the company’s or third-party websites referenced in those releases is not incorporated into the 8-K.

Key Details

• Press releases for both trials were issued March 28, 2026 and attached to the Form 8-K filed March 30, 2026 (Exhibits 99.1 and 99.2).
• Trials named: HI-PEITHO and CHAMPION-AF (no trial outcome details are stated in the 8-K text itself).
• The Form 8-K was signed by Susan Thompson, Vice President, Chief Corporate Counsel and Assistant Secretary, on behalf of Boston Scientific.

Why It Matters

• Clinical trial results can affect a medical-device company’s regulatory pathway, product commercialization timeline and investor expectations around future revenue or pipeline value. The 8-K signals Boston Scientific has new trial information that investors may consider material.
• Retail investors should read the attached press releases (Exhibits 99.1 and 99.2) for the specific results and look for any follow-up SEC filings or company commentary that provide detailed data, regulatory implications, or financial guidance.